Clinical trials: Neoplasms, Oral
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic…
- Trial name
- NCT02150967
- Testing
- BGJ398 (infigratinib)
- Where
- 37 sites in United States, Belgium and 9 more
- Volunteers
- 143 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Healthy
Study Evaluating HKI-272 Administered to Healthy Subjects
Safety and tolerability of HKI-272 in healthy subjects; the influence of food intake on the same.
- Trial name
- NCT00366600
- Testing
- neratinib
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Puma Biotechnology, Inc.
Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult…
- Trial name
- NCT06953960
- Testing
- Surzetoclax, Daratumumab, Dexamethasone
- Where
- 51 sites in United States, Australia and 10 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Advanced Solid Tumor
SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors
This study is an open-label, multicenter, phase 1 study of SyB C-0501 by continuous daily oral administration in patients with advanced solid tumors, who have previously received anticancer therapy and consists of two parts.
- Trial name
- NCT03604679
- Testing
- SyB C-0501
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- SymBio Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer
The primary objectives of this trial were to determine the MTD of BIBF 1120 in combination with carboplatin and paclitaxel, pharmacokinetics and objective response of treatment
- Trial name
- NCT02182232
- Testing
- BIBF 1120, Paclitaxel, Carboplatin
- Volunteers
- 33 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors
A Study of Tor Kinase Inhibitor in Advanced Tumors
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.
- Trial name
- NCT00731263
- Testing
- AZD8055
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
This is a Phase I/II, open-label, preliminary study of safety, tolerability, pharmacokinetics, and efficacy. The study comprises three parts: a Dose Escalation cohort, a Dose Expansion cohort, and an Efficacy Expansion cohort.
- Trial name
- NCT07253116
- Testing
- WJ22096
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing Jingao biomidical technology Co. Ltd.
Colorectal Neoplasms
Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity
Primary Objective: To assess the benefit of glutamine when added to calcium-magnesium on the occurrence of grade 2, 3 and 4 peripheral sensory neuropathy (PSN) related to oxaliplatin with the National Cancer Institute-Common…
- Trial name
- GLUTOX (NCT01087658)
- Testing
- Glutamine, Calcium and Magnesium
- Where
- 14 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Sanofi
Relapsed Advanced Lymphomas
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)
- Trial name
- ADITI-1 (NCT06755450)
- Testing
- AUR112
- Where
- 19 sites in India
- Volunteers
- 40 people
- Sponsor
- Aurigene Discovery Technologies Limited
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
- Trial name
- NCT06136884
- Testing
- AO-252
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- A2A Pharmaceuticals Inc.
Solid Tumors, Adult
Study of ON 123300 in Patients With Advanced Cancer
This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.
- Trial name
- NCT04739293
- Testing
- ON123300
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Traws Pharma, Inc.
Ovarian Cancer
Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145
The goal of this study is to learn more about the study candidate drug, KAND145, when given to healthy volunteers. The study will consist of two parts.
- Trial name
- NCT06063343
- Testing
- KAND145
- Where
- Finland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novakand Pharma AB
Salivary Gland Tumor, Urothelial Carcinoma
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that…
- Conditions
- Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
- Trial name
- NCT04969835
- Testing
- AVA6000
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 158 people
- Sponsor
- Avacta Life Sciences Ltd
Oral Squamous Cell Carcinoma
Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
The study is designed to measure salivary matrix metalloproteinase-1 (MMP-1) using the enzyme-linked immunosorbent assay (ELISA) we developed previously in patients with oral potentially malignant disorders (OPMD), oral squamous…
- Trial name
- NCT05049408
- Testing
- MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
- Where
- 2 sites in Taiwan
- Volunteers
- 1,160 people, healthy volunteers welcome
- Sponsor
- S&T Biomed Co., Ltd.
Ovarian Cancer
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer
The purpose of this study is to evaluate the efficacy, limited pharmacokinetics (PK), and safety of 1,000 mg of Panzem® NCD administered orally four times a day to patients with recurrent or resistant epithelial ovarian cancer.
- Trial name
- NCT00400348
- Testing
- Panzem Nanocrystal Colloidal Dispersion (NCD)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- CASI pharmaceuticals, Inc.
TP53 Y220C Mutation, Advanced Solid Tumors
A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.
- Trial name
- NCT07372625
- Testing
- metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- PMV Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL.
- Trial name
- NCT06428019
- Testing
- Venetoclax, Acalabrutinib, Obinutuzumab
- Where
- 70 sites in United States, Australia and 7 more
- Volunteers
- 170 people
- Sponsor
- AbbVie
Solid Tumor
PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors
HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth.
- Trial name
- NCT04477057
- Testing
- HS-10241
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Polycystic Ovary Syndrome
Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116
This study will be conducted in a single center, double-blind with 6 dose escalation groups to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of BAY1161116.
- Trial name
- NCT03119077
- Testing
- BAY1161116, Itraconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Breast Cancer
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
The aim of this international open-label randomized phase II trial is to evaluate the efficacy and safety of an all-oral combination and two all-intravenous combinations as first-line therapy for HER2-negative mBC patients.
- Trial name
- NCT03887130
- Testing
- oral vinorelbine, Capecitabine, Gemcitabine 1250 mg/m²
- Volunteers
- 152 people
- Sponsor
- Pierre Fabre Medicament
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.